Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Management Tracks

Maraganore leaves Alnylam with an eye for science, a heart for access

An exit interview with the outgoing CEO of Alnylam

December 2, 2021 6:16 AM UTC

As he readies to leave Alnylam, CEO John Maraganore’s legacy will be as much about pushing the envelope on innovative pricing models as creating drugs using an entirely new modality. 

Wednesday’s announcement that Maraganore is joining Arch Venture Partners will mix the two. He has centered his career on building a company out of what was at the time an edgy discovery, and remains passionate about new modalities. At the same time, his heavy focus on access means value-based pricing models will likely permeate his influence on the companies he invests in. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Alnylam Pharmaceuticals Inc.